Company intelligence / Profile preview

Sebacia

Duluth, Georgia, United Statessipderm.com ↗

Ownership: Private
Development stage: Commercial

Overview

Sebacia developed a novel dermatology treatment for acne using gold microparticles activated by dermatology lasers. Clinical trials demonstrated safety and effectiveness for mild to moderate inflammatory acne. The product was cleared for use in the U.S. and EU before the company dissolved. The approach offered an alternative to daily topical or systemic drugs by providing an office-based procedure performed by dermatologists.

Therapeutic areas: GastroenterologyDermatology
Modalities: DeviceNanoparticle (specifically gold microparticles)Non-pharmacological therapy (laser-based procedure)
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

Sebacia Microparticles

Commercial

Indications: Acne vulgaris

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Sebacia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sebacia.

Explore the full profile